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Abstract
Background—Obesity induces significant changes in lipid mediators, however, the extent to 
which these changes persist after weight loss has not been investigated.
Subjects/Methods—We fed C57BL6 mice a high fat diet to generate obesity and then switched 
the diet to a lower fat diet to induce weight loss. We performed a comprehensive metabolic 
profiling of lipid mediators including oxylipins, endocannabinoids, sphingosines and ceramides in 
key metabolic tissues including adipose, liver, muscle, hypothalamus and plasma.
Results—We found that changes induced by obesity were largely reversible in most metabolic 
tissues but the adipose tissue retained a persistent obese metabolic signature. Prostaglandin 
signaling was perturbed in the obese state and lasting increases in PGD2, downstream metabolites 
15-deoxy PGJ2 and delta-12-PGJ2 were observed after weight loss. Furthermore, the enzyme 
responsible for PGD2 synthesis (hematopoietic prostaglandin D synthase, HPGDS) was increased 
in obese adipose tissues and remained high after weight loss. We found that inhibition of HPGDS 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Olivia Osborn, oosborn@ucsd.edu, Address: Stein Clinical Research Bldg. 226, Department of Medicine 
(0673), Division of Endocrinology and Metabolism, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, Tel: 
(858) 822-6645, FAX: (858) 534-665. 
HHS Public Access
Author manuscript
Int J Obes (Lond). Author manuscript; available in PMC 2018 July 23.
Published in final edited form as:
Int J Obes (Lond). 2018 April ; 42(4): 728–736. doi:10.1038/ijo.2017.266.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
over the course of 5 days resulted in decreased food intake in mice. Increased HPGDS expression 
was also observed in human adipose tissues compared with lean individuals. We then measured 
circulating levels of PGD2 in obese patients before and after weight loss and found that while 
elevated relative to lean subjects, levels of this metabolite did not decrease after significant weight 
loss.
Conclusions—These results suggest that lasting changes in lipid mediators induced by obesity, 
still present after weight loss, may play a role in the biological drive to regain weight.
Introduction
In America, an estimated 45 million people attempt to lose weight each year (1) and 
although many achieve short term success, sustained maintenance of reduced body weight is 
rarely achieved (2–9). A successful weight loss program incorporating diet and lifestyle 
changes may lead to 10% reduction in body weight (10), but remarkably 75–95% of people 
regain this weight (2, 9, 11–14). The driving forces behind weight regain include both 
biological and psychological factors (4, 15, 16). Weight loss is associated with 
compensatory decreases in energy expenditure, which opposes the maintenance of the lower 
weight and promotes weight regain (17–21). Furthermore, changes in circulating levels of 
peripheral modulators important in appetite regulation, including leptin, peptide PYY, 
cholecystokinin, insulin, ghrelin gastric inhibitory polypeptide, as well as hunger, remain 
significantly different from baseline one year after weight loss and play an important role in 
weight regain (22).
Obesity induces significant changes in the metabolome (23–27), however, the extent to 
which these changes persist after weight loss has not been investigated. We fed C57BL6 
mice a high fat diet (60% calories from fat, HFD) to generate obesity and then switched the 
diet to a lower fat diet (10% calories from fat, LFD) to induce weight loss (28). In this study 
we have used targeted metabolomics to study changes in lipid mediators in insulin target 
tissues (liver, adipose, muscle, hypothalamus) and plasma, in obesity and after weight loss in 
mice. We performed comprehensive metabolic profiling of lipid mediators including 
oxylipins, endocannabinoids, sphingosines and ceramides that have been implicated in 
obesity associated co-morbidities including insulin resistance, diabetes and cardiovascular 
disease (26, 29–42).
Oxylipins are potent bioactive metabolites that are involved in inflammatory signaling and 
play important roles in obesity-induced inflammation and insulin resistance (26, 34, 35, 39–
41, 43). Oxylipins (eicosanoids, docosanoids, and octadecanoids) are derived from the 
oxygenation of polyunsaturated fatty acids (PUFAs) by three families of enzymes COX, 
lipoxygenase (LOX) and cytochrome p450 (CYP) (43). The 12-LOX derived oxylipins are 
induced in the obese state and studies have shown these oxylipins play an important role in 
mediating inflammation and result in adipocyte dysfunction (44). The endocannabinoid 
system plays an important role in energy storage, nutrient transport and insulin sensitivity 
(29). In the CNS endocannabinoids stimulate food intake through their interactions with the 
leptin-regulated neurocircuitary and can work as neuromodulators able to directly regulate 
and release classical neurotransmitters (45, 46). Endocannabinoids act on peripheral tissues 
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including adipose, liver and muscle and overactive endocannabinoid tone is associated with 
obesity (29, 30, 36–38). Ceramides are bioactive sphingolipids that accumulate in obesity 
resulting in the development of insulin resistance (31–33, 42, 47). Ceramides are 
synthesized by a family of six ceramide synthases (CerS) in mammals, which produce 
ceramides with different N-linked acyl chains of various lengths. Inhibition of ceramide 
synthesis has been shown to improve systemic metabolism and obesity-induced insulin 
resistance (33, 42).
While many studies have identified changes in lipid mediators in obesity, the extent to which 
weight loss reverses these obesity-induced changes has not yet been studied. The 
mechanisms driving weight rebound are complex and largely unknown, therefore, 
understanding the barriers to maintaining weight loss are crucial for the prevention of 
relapse to obesity. We hypothesized that some metabolites induced or repressed in the obese 
state remain so even after weight loss and these “persistent” metabolites may play a role in 
driving weight regain. Metabolites that are induced by obesity and not changed upon weight 
loss will represent therapeutic targets for the maintenance of weight loss.
Materials/Subjects and Methods
In vivo mouse studies
All experiments were approved by and conducted in accordance with the Institutional 
Animal Care and Use Committee (IACUC) at the University of California, San Diego. Male 
C57BL6 mice were fed normal chow until 12 weeks of age and then randomly divided into 
three groups termed LFD (low fat diet, 10% fat; D12450B, Research diets), HFD (high fat 
diet, 60% fat; D12492, Research Diets) and SWD (switch diet from HFD to LFD). The LFD 
and HFD group were fed ad libitum for 18 weeks. The SW group were fed HFD for 9 weeks 
and then switched to LFD for a further 9 weeks after which their body weights had returned 
to a similar mass as the LF group (n=8 per group). Group sizes were selected based on 
previous similar studies (28). All groups were sacrificed at 30 wks of age and the tissues 
(hypothalamus, liver and epididymal adipose tissue) dissected and frozen immediately in 
liquid nitrogen. Glucose Tolerance tests (GTTs) were performed at 3 and 8 weeks after the 
diet switch as previously described (48). Briefly, mice were fasted for 6 hrs and then injected 
with glucose (ip, 1 g/kg dose) and blood samples drawn at 10, 30, 60 and 90 mins to monitor 
glucose excursion over time. A selective inhibitor of hematopoietic prostaglandin D synthase 
(HQL-79, 30 mg/kg, (Cayman Chemical, Ann Arbor, MI) or vehicle control (saline) was 
administered by oral gavage for 5 consecutive days to C57BL6 mice fed HFD 8 wks, from 
12 wks of age. Body weight and food intake was measured daily at 10 AM prior to gavage 
and at the end of the study mice were sacrificed and plasma and adipose tissue collected, 
n=12 mice per group.
Sample extraction
Oxylipins, endocannabinoids, and ceramides were isolated using a 96-well Ostro™ Pass 
Through Sample Preparation Plate (Waters Corp, Milford, MA) n=6 samples per tissue/per 
group. For plasma, 50 µL of sample was added to the plate wells and spiked with a 5 µL 
anti-oxidant solution (0.2 mg/ml solution BHT/EDTA in 1:1 methanolwater) and 10 µL 1000 
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nM deuterated surrogates. Next, isopropanol w/ 10 mM ammonium formate and 1% formic 
acid (150 µL) was added and aspirated three times to mix. Following this step, the mixture 
was eluted into glass inserts, dried, and reconstituted in the same manner as the tissue 
samples (as described below). Tissue samples were pulverized (Liver ~20–25 mg, adipose 
6–10 mg, muscle 6–10 mg hypothalamus ~0.5–2.5 mg) and added to 2 mL polypropylene 
tubes spiked with a 5 µL anti-oxidant solution (0.2 mg/ml solution BHT/EDTA in 1:1 
methanol:water) and 10 µL of 1000 nM deuterated surrogates in methanol. A total of 50 µL 
of methanol was added and the tube was placed in a Geno/Grinder 2000 (SPEX Sample 
Prep, Metuchen, NJ) for 30 sec at 1350 rpm. An additional 550 µL isopropanol w/ 10 mM 
ammonium formate and 1% formic acid and 100 uL water was added and the tube was 
placed in a Geno/Grinder for an additional 30 sec before being centrifuged at 10,000g for 5 
min at room temp. Supernatants were transferred into Ostro Plate wells and eluted into glass 
inserts containing 10 µL 20% glycerol in methanol by applying a vacuum at 15 Hg for 10 
min. Eluents were dried by vacuum centrifugation in a Genvac EZ-2 (SP Scientific, Stone 
Ridge, NY) for 35 min at the medium BP setting, before switching to an aqueous setting for 
an additional 35 min. Once dry, samples were re-constituted with the internal standard 1-
cyclohexylureido, 3-dodecanoic acid (Cayman Chemical) and 1-phenylureido, 3-Hexanoic 
acid (gift from B.D. Hammock, University of California, Davis) at 100 nM (50:50 
methanol:acetonitrile), vortexed 1 min, transferred to a spin filter (0.1 µm PVDF membrane, 
Millipore, Billerica, MA), centrifuged for 3 min at 6°C at <4500 g (rcf), before transfer to 2 
mL LC-MS amber vials. Extracts were stored at −20°C until analysis by ultraperformance 
liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The internal standards 
were used to quantify the recovery of surrogate standards.
Lipid mediator analysis
Analytes were separated using a Waters Acquity UPLC (Waters, Milford, MA) with a 
solvent gradient modified from previously published protocols for oxylipins (40), 
endocannabinoids (39), and ceramides (49). Samples were held at 10°C. Separated residues 
were detected in independent injections by negative mode electrospray ionization for 
oxylipins and positive mode electrospray ionization for endocannabinoids and ceramides 
using multiple reaction monitoring on an API 4000 QTrap (AB Sciex, Framingham, MA, 
USA). Analytes were quantified using internal standard methods and 5 to 7 point calibration 
curves (r2 ≥ 0.997). Calibrants and internal standards were either synthesized [10,11-DHN, 
10,11-DHHep, 10(11)-EpHep] or purchased from Cayman Chemical, Avanti Polar Lipids 
Inc. (Alabaster, AL) or Larodan Fine Lipids (Malmo, Sweden), unless otherwise indicated. 
Data was processed using AB Sciex MultiQuant version 3.0.2. Lipid mediator data from this 
study can be accessed from http://www.metabolomicsworkbench.org, data set refs 
ST000593 and ST000594.
Human samples
Plasma PGD2 levels were determined by ELISA (Cayman chemicals, MI) in samples 
obtained from obese patients before and after bariatric surgery. Specifically, blood samples 
were collected at the following time-points: 1) Plasma samples were obtained 3 weeks prior 
to surgery, after which patients committed to a stringent three week 800 cal/day diet 
regiment. 2) Plasma samples were collected on the day of surgery, at which time the patients 
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had lost on average 8.7 kg due to the diet regime. 3) Plasma samples were also collected 6 
and 12 months after surgery, at which time the patients had lost on average 37.3 kg and 46.7 
kg, respectively. These human samples were obtained from a larger study (ClinicalTrials.gov 
NCT02322073) in agreement with the principal investigator, V. Wallenius. The Regional 
Ethical Review Board (Gothenburg, Sweden), approved all study procedures (Dnr 682-14) 
and all patients were enrolled in accordance with the Helsinki Declaration. Written informed 
consent was obtained from all participants included in this study.
Adipocyte and stromal vascular cell isolation from adipose tissue
Adipocytes and stromal vascular cells were isolated as previously described (50). Briefly, 
visceral adipose tissue was mechanically chopped and then digested with collagenase II for 
15 minutes at 37°C. After passing cells through a 100-µm cell strainer and centrifugation at 
1,000 g for 10 minutes, primary adipocytes were collected from the top layer of the 
supernatant and the pellet containing the stromal vascular fraction (SVC) fraction was then 
incubated with red blood cell lysis buffer.
RNA isolation and q-PCR
Total RNA was isolated using TRIzol (Invitrogen, CA) according to the manufacturer’s 
instructions. First-strand cDNA was synthesized using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA). For q-PCR, samples were run in a 
20-ul reaction (iTaq SYBRgreen supermix; BioRad, CA) using a stepOnePlus Real-Time 
PCR system (Applied Biosystems). Gene expression levels were calculated after 
normalization to the standard housekeeping gene Actb and RNA polymerase II, using the 
ΔΔCt method as described previously (48), and expressed as relative mRNA levels 
compared with internal control. Primer sequences available upon request.
Statistics
When comparing two groups statistical analysis was performed by a 1 or 2-tailed Student’s t 
test. A two way ANOVA with repeated measures followed by a Tukey post hoc test was used 
to compare multiple groups at different time points using GraphPad Prism 6, unless 
otherwise stated. For the lipid analysis, significance was determined by one-way ANOVA on 
log10 transformed data and Benjamini and Hochberg was used for false discovery rate 
adjustment. Significance was defined as q value equal or less than 0.05. All data are 
expressed as mean ± SEM. “Reversibility” was defined as a significant change between the 
lean and obese state (q < 0.05 LFD v HFD), which then changes back after weight loss (q < 
0.05 HFD v SWD), while the level after weight loss is comparable with the original lean 
state (q > 0.05 SWD v LFD). The “persistent’ class contains metabolites that change 
significantly between the lean and obese state (q < 0.05 LFD v HFD), that do not 
significantly change after weight loss (q > 0.05 HFD v SWD) and the new level after weight 
loss is also significantly different from the original LFD level (q < 0.05 SWD v LFD). The 
third class, includes metabolites that are “not fully reversed” after weight loss, where the 
metabolite is significantly changed in the obese state (LFD v HFD), but after weight loss, 
the levels are not significantly different from the HFD level (HFD v SWD not significant), 
and the new level after weight loss is not significantly different from the lean state (SWD v 
LFD not significant). No blinding was carried out for data analysis.
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Results
To identify lipid mediators that are regulated by obesity or weight loss we used a model of 
HFD feeding to induce obesity in C57BL6 mice and then switched the diet to LFD to induce 
weight loss (Fig 1A). Mice chronically fed HFD developed obesity (Fig 1B) and glucose 
intolerance (Fig 1C). Switching from HFD to LFD feeding for a further 9 weeks resulted in 
weight loss (Fig 1D) and improvement in glucose tolerance (Fig 1E) in the SWD group to a 
similar level as mice that were continuously fed LFD throughout the study.
Targeted lipid mediator analysis of endocannabinoids, oxylipins and ceramides in metabolic 
tissues including liver, adipose tissue, skeletal muscle, hypothalamus and plasma, identified 
57 metabolites that were significantly induced or repressed in the obese state compared with 
lean controls (Fig 2). Of these changes the majority were increased in the HFD fed, obese 
state while only 8/57 lipids were lower in the HFD fed mice compared with LFD fed mice 
(Fig 2A). The change in expression levels of metabolites between the lean and obese state 
were classified as either “reversible”, “persistent”, or “not fully reversed” after weight loss. 
The majority of these changes (28/57, = 49%) were reversible after weight loss, while 12/57 
(= 21% are not fully reversed and (17/57, =30%) are persistent and do not revert back to lean 
state after weight loss (Fig.2B).
The majority of changes in lipid mediators occurred in the adipose (25/57 =43%) and liver 
tissues (21/57 = 36.8%), while far fewer were observed in the plasma (8/57=14%), muscle 
(2/57=3.5%) and hypothalamus (1/57=1.8%), (Fig 2C). After weight loss, induced by 
switching the diet from HFD to LFD, many of the obesity/HFD-induced changes observed 
in the adipose tissue were persistent and did not return to the equivalent LFD fed levels, 
while no persistent changes were observed in the liver, muscle, hypothalamus or plasma.
HFD feeding resulted in changes in concentration of lipids across multiple tissues (Fig 2D–
F). For example, oxylipins such as 13-HODE, 9-HOTE, 9-HEPE and 9-HODE all increased 
in both adipose and liver from obese, HFD fed mice compared with lean LFD-fed mice (Fig 
2D). Endocannabinoid-like compounds 1-OG, 2-LG and LEA were all increased in HFD fed 
mice compared with lean, LFD fed mice (Fig 2E). HFD feeding resulted in increased 1-OG 
in the adipose and liver; increased 2-LG in adipose and plasma; and increased LEA across 
adipose tissue, liver, hypothalamus and plasma compared with LFD fed mice. HFD feeding 
resulted in decreased OEA in the liver but increased OEA in the plasma compared with 
LFD-fed mice (Fig 2E). HFD resulted in increased C18:1 and C20 ceramide in adipose, 
muscle and plasma; increased C18 dihydroceramide in adipose and plasma and increased 
18:1 sphingosine in adipose and liver compared with LFD fed mice (Fig 2F). Some of these 
changes were reversible upon weight loss, while some persisted at the level observed in the 
obese state (Fig 2D–F).
The individual lipids that are significantly different in HFD fed mice compared with LFD 
fed mice are classified into reversible, not fully reversible and persistent classes (Fig 3). The 
majority of changes induced by HFD feeding/obesity in the liver (Fig 3A) plasma, muscle 
and hypothalamus (Fig 3B) are reversible after weight loss. In contrast, the majority of the 
changes induced by HFD feeding in adipose tissue are persistent after weight loss (Fig 3C). 
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Of the 25 lipids that significantly change in adipose tissue after HFD feeding only 5/25 had 
fully reversed back to lean levels after weight loss, 3 were partially reversed while 17/25 
were persistently high after weight loss. Of these persistent changes, prostaglandin signaling 
is perturbed with lasting increases in PGD2 and downstream metabolites Delta-12-PGJ2 and 
15-deoxy PGJ2 (Fig. 3D & E) in adipose tissue. Notably other cyclooxygenase-dependent 
metabolites including TXB2, 6-keto PGF1a and PGE2 (Fig 3E) were not induced by HFD 
feeding.
Cyclooxygenase-dependent metabolites, including the prostaglandins (PGs) and 
thromboxanes (TXs) have broad roles in both healthy and pathological contexts (51). 
Cycloxygenase enzymes catalyze the conversion of arachidonic acid to PGH2, which is 
converted to species including PGD2, PGE2, PGF2a, prostacyclin (PGI2) or TXA2 by the 
action of specific synthases (52). PGD2 is further dehydrated to produce PGJ2, delta 12-
PGJ2, and 15-deoxy-delta 12,14-PGJ2. The synthesis of PGD2 from PGH2 can be catalyzed 
by two synthase enzymes termed prostaglandin D synthase (PTGDS) (53) and hematopoietic 
prostaglandin D synthase (HPGDS) (54). HPGDS is widely distributed in the peripheral 
tissues while PTGDS is highly expressed in the central nervous system, but also expressed at 
lower levels in other peripheral tissues (55). We therefore measured the expression of 
HPGDS and PTGDS enzymes in adipose tissue from these three diet groups. HPGDS was 
increased in HFD fed mice by ~10 fold compared with LFD fed mice and the expression 
level remained high in the SWD group (Fig. 4A), while PTGDS was unchanged between 
groups (Fig. 4B). To determine the cellular source of HPGDS in adipose tissue we 
fractionated the adipocytes and SVCs from LFD, HFD and SWD fed mice (Fig 4C). Levels 
of HPGDS were similar between adipocytes and SVCs from LFD fed mice. However, after 
HFD feeding the levels of HPGDS increased significantly in both adipocytes and SVCs 
compared with LFD fed mice and this increase persisted in both adipocyte and SVC 
fractions after weight loss (Fig 4C). In agreement with other studies (56), we also observed 
persistent expression of macrophage markers after weight loss (Fig 4 D and E).
To determine whether these findings were also conserved in human subjects we measured 
the levels of these enzymes in human adipose tissue biopsies taken from lean and obese 
patients. We previously performed microarray analysis on human adipose tissue biopsies 
(57) and mined this dataset to determine if HPGDS was differentially expressed between 
lean and obese individuals. HPGDS levels were increased ~1.95 fold compared with lean 
individuals (BMI 23.2 v 35.9) (Fig. 4F). This increase in HPGDS in adipose tissue from 
obese patients was also observed when we extracted the expression data from similar 
published studies (Fig 4G), NCBI GEO dataset GDS3679 (58). We then extracted data from 
studies comparing expression levels in adipose tissue before and after weight loss (59, 60) 
and looked at HPGDS levels to see if obesity-induced increase in HPGDS was maintained 
after weight loss as seen in our mouse studies. In support of the mouse data, diet induced 
weight loss of up to 15% (Fig 4H) (59), or after a very low calorie diet for 16wks with 
average weight loss of 27.7 kg (Fig 4I) (60) did not change the expression levels of HPGDS 
in human adipose tissue. We also measured circulating levels of PGD2 in obese subjects 
before and after gastric bypass surgery (Fig 4J–K). Circulating levels of PGD2 in obese 
patients were approximately 2 fold higher than the clinical reference rage for normal 
individuals (57, 61–64). Furthermore, after substantial weight loss of ~35% (average BMI 
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reduced from 43.6 to 28.2) PGD2 levels were unchanged one year after gastric bypass 
surgery.
Due to the persistent elevation of PGD2 and HPGDS we hypothesized that PGD2 may play 
a role in food intake. Central injection of PGD2 has previously been shown to stimulate food 
intake (65) but whether peripheral levels of PGD2 could play a role in food intake is not yet 
known. To reduce peripheral levels of PGD2 we treated mice with the selective HPGDS 
inhibitor HQL-79 (66). Previous studies have shown that HQL-79 selectively inhibits 
HPGDS while not affecting PTGDS and results in lowering of PGD2 levels (67–69). 
Treatment of wild type, HFD fed mice with HQL-79 (30mg/kg, oral gavage) for 5 days 
resulted in a significant reduction in food intake (Fig 5A), with an associated trend in 
reduction of body weight (p=0.09) (Fig 5A). Whole adipose tissue levels of PGD2 in whole 
adipose tissue were not significantly different between the control and HQL-79 treatment 
groups, but the ratios between PGD2 and other connected pathway metabolites indicate a 
shift toward the production of PGE2 and PGF2a, in addition to their metabolites, instead of 
PGD2 (Supplemental figure 1) after HQL-79 treatment.
Discussion
We hypothesized that lasting changes in the metabolome after weight loss may play a role in 
feeding behavior and contribute to weight regain. We characterized changes in the levels of 
oxylipins, endocannabinoid and ceramide lipid mediators in lean, obese and weight-reduced 
mice. We identified lasting changes in the lipid mediators in the weight-reduced mice and 
identified many persistent changes specifically in adipose tissue. Of these persistent changes, 
prostaglandin signaling was perturbed with persistent elevation in PGD2 and downstream 
metabolites 15-deoxy PGJ2 and delta-12-PGJ2. In addition, levels of the enzyme responsible 
for PGD2 synthesis (HPGDS) were also increased in adipose tissue in the obese state and 
did not decrease after weight loss in both mouse and human studies.
PGD2 plays a broad role in many biological processes including sleep (70), analgesia (71) 
allergic diseases (52, 72) and food intake, where injection of PGD2 directly into the brain 
increases food intake in mice (65). Prostanoids exert a wide variety of actions in the body, 
which are mediated by specific receptors on plasma membranes (73). PGD2 acts through 
two receptors (DP1 and DP2 CRTH2), whereas 15-deoxy PGJ2 can activate some 
peroxisome proliferator-activated receptors and inhibit proinflammatory pathways (74). Our 
finding that levels of prostaglandin signaling increased in obesity are in agreement with 
previous published studies showing elevated PGD2 and HPGDS in mouse adipose tissue 
(75). Furthermore, transgenic overexpression of H-PGDS in mice results in obesity and 
increased fat mass (76). We confirm and extend these findings by showing this obesity-
induced increase in PGD2 does not decrease after weight loss and may play a role in body 
weight regulation.
In human studies, prostaglandin signaling has been linked to obesity in correlation studies 
showing that expression of the prostaglandin synthesis enzyme PTGDS in the cerebrospinal 
fluid significantly correlated with levels of orexigenic neuropeptides (77). In addition, 
PTGDS levels in CSF are positively correlated with visceral adipose tissue and negatively 
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correlated with subcutaneous adipose tissue mass (77). In our studies we have mined 
expression databases of human adipose tissue from lean and obese subjects and found levels 
of HPGDS were elevated in the obese state and did not decrease after weight loss. In 
addition circulating levels of PGD2 were elevated compared with the lean reference range, 
and gastric bypass-induced weight loss did not decrease circulating PGD2 levels.
The lasting changes in prostaglandin signaling in adipose tissue after weight loss suggest a 
possible role in weight regain. Previous studies have shown that central injection of PGD2 
stimulates food intake, (65) but whether peripheral levels of PGD2 could play a role in food 
intake was not yet known. We show that inhibition of HPGDS (by oral gavage of HQL-79) 
results in decreased food intake and thus could be a therapeutic strategy in prevention of 
weight regain after weight loss. After 5 days of HQL-79 administration in HFD fed mice the 
adipose tissue ratios between PGD2 and other connected pathway metabolites indicate a 
shift toward PGE2 and PGF2a production instead of PGD2 after HQL-79 treatment 
(Supplemental fig 1A), however, detected levels of PGD2 were not significantly different in 
whole adipose tissue. Fractionating the adipocyte and SVF would determine whether either 
cell type up-regulate PGD2 production in response to HPGDS inhibition (67) but the 
isolation procedure itself will likely cause alterations in metabolite levels that would no 
longer reflect the in vivo state (75) due to rapid degradation of PGD2 within a few minutes 
(78). Furthermore, although we give the H-PGDS inhibitor peripherally, we cannot rule out 
the possibility that this inhibitor may also act directly on the brain to reduce PGD2 levels 
which may also play a role in the observed effects on food intake. Future studies are needed 
to fully understand the role of adipocyte and SVC PGD2 levels on the regulation of food 
intake and energy expenditure. There are currently specific HPGDS inhibitors being 
developed for other indications including asthma and chronic obstructive pulmonary disease 
(79, 80). Our data strongly suggests that inhibition of HPGDS may also be beneficial to 
maintain weight loss and prevent weight regain.
The role of adipose tissue in the control of food intake is well established, with leptin being 
the most well known example (81), but how peripheral levels of PGD2 may affect feeding 
behavior is still unknown. Body weight is controlled centrally by the hypothalamus which 
integrates signals emanating from the periphery including gastrointestinal, hepatic, and 
adipose tissue to control food intake and energy expenditure (82) (83). PGD2 from adipose 
tissue may travel via the systemic circulation, crossing the blood brain barrier and directly 
reach the brain (82). However, we do not observe a significant increase in PGD2 levels in the 
plasma of obese mice, which may be due to instability of this metabolite that has a half-life 
in the blood of less than 2 mins (78), (Supplemental Table 1). Alternatively, the signal from 
adipose to brain may be transduced by changes in the firing rate of sensory nerve fibers. 
Viral tracing studies have identified afferent circuits projecting from WAT to the central 
nervous system, supporting the existence of a sensory WAT pathway to the brain (84, 85). 
Therefore, further investigation is needed to understand the mechanism by which adipose 
tissue levels of lipid mediators may regulate food intake.
Despite the persistent metabolic adaptions that act to proportionally counter efforts to reduce 
body weight (86), some studies report that weight loss maintenance gets easier over time: 
after individuals have successfully maintained weight loss for 2–5yrs the chances of longer 
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term success greatly increases (9). Human adipocytes turn over very slowly, and on average 
are only replaced every 10 years (87, 88). Therefore, changes induced in adipocytes by 
obesity may be longer lasting than in cell types that are replaced more readily. In addition, 
the obesity-induced increase in macrophage infiltration into adipose tissue does not reverse 
after weight loss and these cells are still present in adipose tissue after sustained weight loss 
in mice (56). Therefore, the “metabolic memory” of adipose tissue is difficult to erase even 
after maintenance of weight loss. In future time course studies, it will be interesting to see if 
the persistent changes in the adipose metabolome will eventually reverse after a longer time 
frame.
These studies reveal that obesity induces a lasting metabolic signature that does not resolve 
after weight loss. This metabolic signature resides predominantly in adipose tissue while 
other metabolic tissues including liver, muscle and hypothalamus return to pre-obese levels 
after weight loss. We show that PGD2 signaling is implicated in food intake and that high 
levels of HPGDS and circulating PGD2 are still present in human subjects despite weight 
loss. The metabolic characteristics of adipose tissues after weight loss could play an 
important role in the persistence of a biological drive to regain weight.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Model of obesity and weight loss in mice
A) Male C57BL6 mice were fed normal chow (NC) until 12 weeks of age, and then divided 
into three groups fed either low fat diet (LFD) or high fat diet (HFD) for a further 18 weeks, 
or HFD for 9 weeks and then switched to LFD for 9 weeks to induce weight loss (SWD). B) 
Body weights after 9 wks of LFD or HFD feeding. C) GTT after 9 weeks of feeding HFD or 
LFD. D) Body weights 8 wks after the diet switch E) GTT, 8 weeks after the diet switch. 
Significance was defined as p-value equal or less that 0.05. *, values labeled with different 
letters are significantly different.
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Figure 2. Targeted analysis of lipid mediators: Oxylipins, Endocannabinoids and Ceramides
A) Changes in lipid mediators observed between the lean (LFD) and obese (HFD) state 
across all tissues (liver, adipose, skeletal muscle, hypothalamus and plasma). B) The effect 
of weight loss on lipid mediators that were significantly changed in the obese state versus 
lean; defined as reversible, persistent and not fully reversible after weight loss induced by 
LFD feeding. C). Number of metabolites that are reversible, persistent, or not fully 
reversible within each tissue. Concentration of D) Oxylipins, E) Endocannabinoids and F) 
Ceramides. Lipid analysis significance was determined by One-Way ANOVA on log10 
transformed data and Benjamini and Hochberg false discovery rate was used for multiple 
comparison adjustments. All data are expressed as mean ± SEM. Significance was defined 
as q-value equal or less that 0.05. *, Significant change between LFD and HFD, # reversible 
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change after LFD feeding, $, not fully reversible after LFD feeding, & persistent change 
after diet switch.
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Figure 3. Persistent increase in PGD2 levels after weight loss
Heatmaps compare levels of lipid mediators across the three diet groups (LFD, HFD and 
SWD). A) Liver. B) Plasma, muscle and hypothalamus. C) Adipose. Lipids shaded green are 
reversible, grey = not fully reversible, orange = persistent. Fold change is reflected by 
intensity of color blue (decreased) to red (increased). D) Pathway of prostaglandin synthesis. 
Cycloxygenase enzymes catalyze the conversion of arachidonic acid to PGH2, which is 
converted to other species including PGD2, PGE2, PGF2a, prostacyclin (PGI2) and 
thromboxane (TX) A2 by the action of specific synthases. E) Prostaglandin levels in lean 
(LFD), obese (HFD fed) and after weight loss (SWD).
Hernandez-Carretero et al. Page 20
Int J Obes (Lond). Author manuscript; available in PMC 2018 July 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Obesity-induced increase in prostaglandin D2 signaling does not decrease after weight 
loss
A) Relative expression of HPGDS in adipose tissue from LFD, HFD and SWD mice. B) 
Relative expression of PTGDS in adipose tissue from LFD, HFD and SWD mice. C) 
HPGDS expression in adipocyte and stromal vascular cells (SVC) from LFD, HFD and 
SWD mice. D) F4/80 and E) CD11c expression in SVC from LFD, HFD and SWD mice. F) 
Expression of H-PGDS in adipose tissue biopsies from lean (n=6, BMI 23.2 ± 0.8) and 
obese (n= 35, BMI 35.9 ± 1.1) individuals, * q < 0.05 (57). G) Lean and obese omental 
adipose tissue, NCBI GEO dataset GDS3679 (58), 1 –tailed t-test, q < 0.1. H) Before and 
after weight loss of 5, 10 and 15% (59). I) Before and after weight loss induced by very low 
calorie diet for 16wks (60). J) BMI of patients before and after bariatric surgery. K) Plasma 
PGD2 levels in obese patients before and after gastric bypass surgery. Significance was 
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defined as q-value equal or less that 0.05. *, values labeled with different letters are 
significantly different.
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Figure 5. Food intake and body weight changes in mice treated with HPGDS inhibitor
A) Average daily food intake (kcal) and B) body weight change in HFD fed C57BL6 male 
mice treated with HPGD2 inhibitor (HQL-79, 30 mg/kg, daily oral gavage) for 5 days (n=12 
per group).
Hernandez-Carretero et al. Page 23
Int J Obes (Lond). Author manuscript; available in PMC 2018 July 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
